Leadership

Leadership Team

Meet our executive leaders, board of directors and scientific advisory board.

Board of Directors

Dr. Douglas has served on our board of directors since September 2016. Dr. Douglas is the former Senior Vice President, Corporate Development of Genzyme Corporation. Since 2011, Dr. Douglas has been an independent consultant and advisor at Red Sky Partners LLC. From 1989 to 2011, he led Genzyme Corporation’s Corporate Development team, and was involved in numerous acquisitions, licenses, financings, joint ventures, and strategic alliances. From 1982 until its merger with Genzyme Corporation in 1989 (now Sanofi Genzyme), Dr. Douglas served in science and corporate development capacities at Integrated Genetics. Currently, Dr. Douglas is on the Board of Directors of Novavax, Inc., a publicly traded clinical-stage vaccine company, and he also serves on the University of Michigan Technology Transfer National Advisory Board. Dr. Douglas received a B.S. in chemistry from the University of Michigan and a Ph.D. in biochemistry from the University of California, Berkeley, and he was a postdoctoral fellow in Leroy Hood’s laboratory at the California Institute of Technology.
Todd C. Brady, M.D., Ph.D., has served as our President and Chief Executive Officer since January of 2012 and as a member of our board of directors since 2005. Prior to Aldeyra, Dr. Brady served as Entrepreneur in Residence at Domain Associates, LLC, a leading healthcare venture capital firm, where he was a Principal from 2004 to 2013. Dr. Brady currently serves on the board of directors of Evoke Pharma, Inc. and Spring Bank Pharmaceuticals, Inc., both of which are publicly traded healthcare companies. Dr. Brady holds a Ph.D. in pathology from Duke University Graduate School, an M.D. from Duke University Medical School, and an A.B. from Dartmouth College in Philosophy and Psychology.
Dr. Bronstein has served as a member of our board of directors since 2010, and from 2010 to 2011 served as Chief Executive Officer of Aldeyra, then known as Neuron Systems. Dr. Bronstein is an independent consultant to life science companies at Cold Spring Venture Advisors, where he has been the sole proprietor since September 2009. He has spent the past 27 years in entrepreneurial roles in life science companies and venture capital firms. Most recently, from January 2014 to August 2015, he was Chief Medical Officer of Stealth BioTherapeutics, a privately held company developing pharmaceuticals for serious diseases associated with mitochondrial dysfunction, prior to which he was a Visiting Scholar at the Wyss Institute of Biologically Inspired Engineering at Harvard Medical School from January 2013 to July 2014. Dr. Bronstein has founded or held senior management positions at several venture-backed life science firms, including OKPO Health, a life science company developing human therapeutics and diagnostics, from May 2008 to November 2009, and Vidus Ocular, Inc., a Yale University spinout developing an implantable device for the treatment of glaucoma, from November 2006 to May 2008. He has also held senior roles in life science investment firms including as a founder and senior vice president of Access BridgeGap Ventures, the life science investment unit of Access Industries, Inc., from January 2012 to December 2012. Dr. Bronstein has served on the boards of directors of several privately held life science companies. He is also a member of the Weill Cornell Medical College Faculty Industry Council. He is a board-certified pathologist and dermatopathologist, with over 20 publications. Dr. Bronstein began his professional career on the staff of the Massachusetts General Hospital and on the faculty of Harvard Medical School. He received his M.D. and M.B.A. from Boston University.
Mr. Joyce has served as member of our board of directors since October 2013. Mr. Joyce’s professional background includes leadership roles in public and private, medical device, biotechnology and pharmaceutical companies. He has experience in public equity financings, business development, SEC reporting, strategic planning, mergers, acquisitions, investor relations and biotechnology operations. Since 2012, Mr. Joyce has served as a consultant to the life science industry assisting biotechnology and pharmaceutical companies in strategic planning, fundraising and operations. From March 2011 to July 2012, Mr. Joyce was Chief Financial Officer at Lucid Inc., an early stage skin cancer diagnostic company. Previously, Mr. Joyce served as Executive Vice President and Chief Financial Officer of BioSphere Medical from January 2006 through September 2010. He served as BioSphere’s Chief Financial Officer and Vice President from September 2004 to January 2006. From January 2001 to September 2004, Mr. Joyce served as Managing Partner of Stratex Group LLC, a provider of biopharmaceutical executive services to early-stage companies and venture investors. From 1996 to January 2001, Mr. Joyce was North American Chief Financial Officer for Serono Inc. a biotechnology company. From April 1987 to 1996, Mr. Joyce held a variety of senior level positions within Serono in finance, sales, marketing and manufacturing. Mr. Joyce was previously employed at Millipore Corporation, a high technology bioscience company. Mr. Joyce received a B.S. in finance from Northeastern University and a M.B.A. from Suffolk University, Boston, Massachusetts.
Dr. Phillips has been a member of our board of directors since May 2009. He has served as OrphoMed’s President and Chief Executive Officer since April 2018. Dr. Phillips has over two decades of experience in the pharmaceutical and healthcare industries, leading commercial operations, clinical medicine, business strategy, and development functions. Dr. Phillips worked with Mallinckrodt Pharmaceuticals, where he served as Executive Vice President and Chief Strategy Officer.  He was President of Reckitt Benckiser Pharmaceuticals, Inc. from 2011 to 2012. He served as President of U.S. Surgical and Pharmaceuticals at Bausch & Lomb Incorporated from 2002 to 2008. Dr. Phillips has also held executive roles at Merck Serono SA from 2008 to 2011, Novartis Corporation from 2000 to 2002, and Wyeth Pharmaceuticals, Inc. (now Pfizer, Inc.) from 1999 to 2000. He was most recently Head of Global Health & Healthcare Industries at the World Economic Forum in Geneva from January 2012 to September 2013. Dr. Phillips was also healthcare strategy managing consultant at Towers Perrin from 1997 to 1999, and practiced as a general medicine clinician/officer in the US Navy, from which he was honorably discharged as a lieutenant commander. Dr. Phillips was educated at the University of Pennsylvania, where he received an M.D. (Alpha Omega Alpha) from the School of Medicine in 1992, an M.B.A. from the Wharton School in 1991, and B.A. (summa cum laude, Phi Beta Kappa) in biochemistry from the College of Arts and Sciences in 1987. He completed postgraduate medical education at Naval Medical Center San Diego and maintains an active medical license.
Dr. Walker has served on our board of directors since June 2013. Dr. Walker is the President and Chief Executive Officer and a director at Aclaris Therapeutics, Inc., a publicly-traded dermatological drug development company. Prior to founding Aclaris Therapeutics, Inc. in 2012, he was co-founder, President and CEO of Vicept Therapeutics, Inc. (acquired by Allergan, Inc.) from 2009 to 2012. Dr. Walker has co-founded and led a number of life science companies: Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc); Trigenesis Therapeutics, Inc., a specialty dermatology company where he served as Chief Medical Officer (acquired by Dr. Reddy’s Laboratories Ltd); Cutix Inc., a commercial dermatology company that markets PreSun®, a sunscreen brand acquired from Bristol-Myers Squibb Co. He began his pharmaceutical industry career at Johnson and Johnson, Inc. Dr. Walker currently is on the Board of Directors of Aclaris Therapeutics, Inc., Sebacia, Inc. and Follica, Inc. (Executive Chairman). Dr. Walker previously served on the Board of Directors for Octagon, a contract research organization. He is also on the Advisory Board of Flexible Medical Systems LLC, a privately held medical device company. Dr. Walker received his MBA from The Wharton School, University of Pennsylvania, his D.O. from Philadelphia College of Osteopathic Medicine and a B.A. in Biology from Lehigh University. He is a board-certified dermatologist.

Scientific Advisory Board – Retina

Dr. Jay S. Duker, M.D., serves on the Aldeyra Therapeutics Retina Scientific Advisory Board and is the Director of the New England Eye Center (NEEC), one of the largest academic, multi-specialty ophthalmology practices in the United States.  He is also Professor and Chairman of the Department of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine in Boston. Dr. Duker received his medical degree magna cum laude from Jefferson Medical College. He completed both his ophthalmology residency and his two year fellowship in vitreo-retinal diseases at the Wills Eye Hospital in Philadelphia. His clinical practice is limited to medical and surgical diseases of the posterior segment with particular emphasis on macular diseases, posterior uveitis and intraocular tumors.   Dr. Duker has published over 250 journal articles, with his major research interests, which include retinal imaging and in particular, optical coherence tomography (OCT), retinal vascular diseases and drug delivery to the posterior segment. His book, Yanoff and Duker’s Ophthalmology, is one of the best-selling ophthalmic texts over the past decade. He is the editor-in-chief of the International Journal of Retina and Vitreous (IJRV) and serves on the editorial board of OSLI Retina. Dr. Duker is the co-founder of three companies, including Hemera Biosciences, a clinical stage biotech whose focus is a gene-therapy-based treatment for age-related macular degeneration. He is also a Director of two publicly traded biotech companies –  Eleven Biotherapeutics, a clinical-stage targeted protein engineering company concentrating on oncologic indications and pSivida which specializes in sustained release drug delivery.
Dr. Dean Eliott, M.D., serves on the Aldeyra Therapeutics Retina Scientific Advisory Board.  He is the Stelios Evangelos Gragoudas Associate Professor of Ophthalmology at Harvard Medical School, Director of the Retina Service at Massachusetts Eye and Ear Infirmary, Director of the Retina Fellowship at Harvard / Mass. Eye and Ear, and Co-Founder of Helio Vision. Dr. Eliott enjoys a national reputation as a talented vitreoretinal surgeon and is sought by colleagues for difficult surgical cases. He is especially interested in treating retinal detachment, proliferative vitreoretinopathy, diabetic retinopathy, eye trauma, and complex vitreoretinal surgical problems.   Dr. Eliott received his undergraduate degree with honors from Duke University, and he received his medical degree with honors from Vanderbilt University School of Medicine. He completed his residency at the highly regarded Wilmer Eye Institute of Johns Hopkins Hospital. He received his retina fellowship training at the Duke Eye Center of Duke University Medical Center, working with Dr. Robert Machemer, who is considered the father of modern vitreous surgery for performing the first vitrectomy. Dr. Eliott then served as Chief Resident and retina faculty member at the Duke Eye Center. Following this, Dr. Eliott was the Director of the Retina Service, Associate Professor, and Retina Fellowship Director at the Kresge Eye Institute of Wayne State University School of Medicine. Subsequently, he was the Director of the Doheny Retina Institute, Professor, and Retina Fellowship Director at the Doheny Eye Institute of the University of Southern California Keck School of Medicine.
Dr. Jeffrey S. Heier, M.D., serves on the Aldeyra Therapeutics Retina Scientific Advisory Board and is the Co-President and Medical Director, Director of the Vitreoretinal Service, and Director of Retina Research at Ophthalmic Consultants of Boston (OCB), one of the largest and most prestigious multi-specialty ophthalmology practices in the United States. Dr. Heier received his medical degree from Boston University, then did a transitional internship and ophthalmology residency at Fitzsimons Army Medical Center. Between his internship and residency, Dr. Heier served as a physician in a Combat Support Hospital in the Persian Gulf War, where he was awarded a Bronze Star. Dr. Heier then completed a vitreoretinal fellowship at Ophthalmic Consultants of Boston/Tufts University School of Medicine. Dr. Heier is on the Executive Board of the Retina Society, the Executive Committee of the American Society of Retina Specialists, past President of the New England Ophthalmological Society, and a member of the Macula Society. Dr. Heier is the past Secretary of Online Education for the American Academy of Ophthalmology and the past President of the Center for Eye Research and Education Foundation in Boston, MA. From the American Academy of Ophthalmology, Dr. Heier received the Senior Achievement Award in 2010, the Secretariat Award in 2007, and the Honor Award in 2003. He is also the recipient of the Honor Award and Senior Honor Award from the American Society of Retina Specialists. Dr. Heier is one of the leading retinal clinical researchers in the country for new treatments in exudative and non-exudative macular degeneration, diabetic macular edema, venous occlusive disease, vitreoretinal surgical techniques and instrumentation, and diagnostic imaging of the retina. He serves on the Scientific Advisory Board or as Clinical Design Consultant to over thirty bio-technology and pharmaceutical companies. Dr. Heier is the lead investigator on numerous clinical trials, ranging from phase I safety and proof of concept trials to phase IV post-marketing studies. Dr. Heier lectures nationally and internationally on retinal research and the innovative approach to the treatment of retinal diseases. He has authored or co-authored numerous works in peer-reviewed journals, as well as served as a reviewer for the New England Journal of Medicine, Lancet, Ophthalmology, Archives of Ophthalmology, American Journal of Ophthalmology, Retina, and numerous other journals.
Dr. Quan Nguyen, M.D. is a member of Aldeyra’s Retinal Advisory Board.  He was born in Saigon, Vietnam, and immigrated with his parents and three brothers to the United States in 1980, Dr. Quan Dong Nguyen currently is Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine. After completing his education in 2001, Dr. Nguyen joined the faculty at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, as Assistant Professor and then Associate Professor of Ophthalmology and Director of Medical Education. In 2013, he was appointed as the McGaw Endowed Chair in Ophthalmology, Professor and Chairman of the Department of Ophthalmology and the Inaugural Director of the Stanley M. Truhlsen Eye Institute, and Assistant Dean for Translational Research at the University of Nebraska Medical Center. Dr. Nguyen serves as principal investigator on multiple clinical trials sponsored by the National Eye Institute and other organizations for macular edema (from diabetes and uveitis), neovascular age-related macular degeneration (AMD), and ocular inflammatory and uveitic diseases, as well as co-investigator on numerous other clinical trials involving novel therapeutic agents. Dr. Nguyen is known for his innovative work in early proof-of-concept, first-in-human clinical trials to evaluate potential pharmacotherapeutic agents for retinal vascular and uveitic diseases. Dr. Nguyen and his team were among the first clinician scientists in the world to evaluate aflibercept for neovascular AMD and ranibizumab for diabetic macular edema (DME); the initial results of these studies served as the foundation for subsequent trials leading to the approval of these pharmacologic agents by the FDA and other regulatory authorities for the indicated diseases. Dr. Nguyen has chaired the United States multi-center READ-2, READ-3, and iDEAL studies, evaluating the potential role of VEGF antagonists, through different pathways, for diabetic macular edema. Dr. Nguyen has lead the SAVE, and the multi-centered SAVE-2, and STOP-UVEITIS studies to evaluate the role of new pharmacologic agents, including specific interleukin inhibition, in uveitis and ocular inflammatory diseases.
Dr. Carl Regillo was a Phi Kappa Phi graduate of Northeastern University, College of Pharmacy, where he was the class Valedictorian.  He received his medical degree from Harvard Medical School on a full military scholarship. He performed his internship in internal medicine at Harvard’s Brigham and Women’s Hospital in Boston, and both his ophthalmology residency and vitreoretinal fellowship at Wills Eye Hospital in Philadelphia. He was appointed the Co-Chief Resident and awarded a Heed Ophthalmic Fellowship during his postgraduate training.   After training, he was commissioned a Major in the United States Air Force and stationed four years as a vitreoretinal surgeon at the San Diego Naval Medical Center.  There he was Co-Director of the Ophthalmology Department’s Retina Service, Assistant Professor of Ophthalmology at the University of California, San Diego, and recipient of a Naval Commendation medal and the Ophthalmology Department’s annual teaching award.  In 1998, he returned to Philadelphia to join Mid Atlantic Retina and the Retina Service of Wills Eye Hospital. Dr. Regillo is currently the Director of the Retina Service of Wills Eye Hospital, Professor of Ophthalmology at Thomas Jefferson University School of Medicine, and Principle Investigator of numerous major international clinical trials investigating new forms of treatment for macular degeneration, diabetic retinopathy, and a variety of other retinal conditions.  He is the founder and former Director of the Wills Eye Clinical Retina Research Unit, prior Chairman of the Wills Eye Institutional Review Board and prior Chairman of the American Academy’s Basic and Clinical Science Course (BCSC) Retina Section committee. He is the former Wills Retina Fellowship Program Director. Dr. Regillo has authored over 200 scientific papers, lectured nationally and abroad, and has published 9 major textbooks in the field. He has served on the scientific editorial board for the American Journal of Ophthalmology, Review of Ophthalmology, Current Opinion in Ophthalmology, Yearbook of Ophthalmology, Retinal Physician, and Retina Today.  He is a fellow of the American College of Surgeons and an active member of the American Academy of Ophthalmology, The Retina Society, The Macula Society, and The American Society of Retina Specialists. He is a former examiner for the American Board of Ophthalmology and a recipient of the American Academy of Ophthalmology Achievement, Senior Achievement, Secretariat, and Lifetime Achievement Awards along with the America Society of Retina Specialists Honor and Senior Honor Awards.  He was named one of the “150 Top Innovators in Retina” by Ocular Surgery News and selected a Charter Inductee of the Retina Hall of Fame. He also has been listed multiple times through the years as a retina “Top Doctor” in the Philadelphia Magazine, Philadelphia Life, Mainline Today and South Jersey Magazine.

Scientific Advisory Board – Anterior Segment

Dr. David Chu, M.D. is currently a member of Aldeyra’s Anterior Segment Scientific Advisory Board.  He is an international key opinion leader in areas of uveitis, ocular immunology and cornea surgeries. He is currently acting as a principal investigator in numerous research projects and clinical trials. In 2006, Dr. Chu was the first to report the outbreak of Fusarium Keratitis associated with use of Renu with Moisture Loc contact lens solution in America to the Federal Health Authority. After the FDA & CDC investigation, he was credited for identifying the link between Bausch & Lomb contact lens solution and the sight threatening fungal cornea infection which was featured in the NY Times. He lectures and teaches nationally and abroad along with providing cutting edge patient care. He is the first surgeon to perform DMEK and DSEK procedures, the least invasive forms of cornea transplantation, in the New York and New Jersey metro area. Dr. Chu also serves as Team Physician for the NY Jets.
Dr. Holland, M.D., is a member of Aldeyra’s Anterior Segment Scientific Advisory Board.  He is the Director of Cornea Services at Cincinnati Eye Institute and Professor of Ophthalmology at the University of Cincinnati. He attended the Loyola-Stritch School of Medicine in Chicago and trained in Ophthalmology at the University of Minnesota. He completed a fellowship in cornea and external disease at the University of Iowa, and then completed a second fellowship in ocular immunology at the National Eye Institute, National Institutes of Health in Bethesda, Maryland. He returned to serve as Director of Cornea and Refractive Surgery Service at the University of Minnesota. He was promoted to the position of Professor and was granted the Elias Potter Lyon Chair in Ophthalmology. He also served as President of the Minnesota Academy of Ophthalmology. Dr. Holland formerly served as the President for the American Society of Cataract and Refractive Surgery from 2011-2012. He was also a member of the Executive Committee and now serves as the Program Chair. Dr. Holland was a former member of the Board of Trustees for the American Academy of Ophthalmology. He has also been the Secretariat of the Annual Meeting for the American Academy of Ophthalmology. He was awarded the Life Achievement Honor Award at the 2012 American Academy of Ophthalmology Annual Meeting. Dr. Holland has served as the Chair of the Eye Bank Association and was the former Chair of the Medical Advisory Board for the Eye Bank Association of America. He is the past President of the Cornea Society and previously served on its Board of Directors. Dr. Holland has been awarded the Castroviejo Award from the Cornea Society in 2013. He has also received both the Senior Achievement Award and The Honor Award from the American Academy of Ophthalmology. He was awarded the Binkhorst Medal by the American Society of Cataract and Refractive Surgery in 2008. He was a recipient of the 2002 Paton Society Award given by the Eye Bank Association of America. Among other honors, Dr. Holland has been listed in the “Best Doctors in America.” He has a national and international reputation for his knowledge and expertise in the field of cornea and external disease. He is frequently invited to attend lectures both nationally and internationally. Dr. Holland is the author of over 200 articles in peer review journals and has edited Cornea, the most widely read textbook on corneal disease and surgery. As the Director of Cornea Services at the Cincinnati Eye Institute, Dr. Holland has attracted worldwide referrals for medical and surgical corneal problems and for stem cell transplantation. His clinical interests include Corneal Transplantation, Cataract Surgery, and Ocular Surface Transplantation.
Dr. Victor Perez, M.D., is presently a member of Aldeyra’s Anterior Segment Scientific Advisory Board.  Dr. Perez joined Duke Ophthalmology in September 2017 as Professor of Ophthalmology. He is an established clinician-scientist investigator in the field of ocular immunology and ocular surface diseases and will be the director of Duke Eye Center’s newly launched Ocular Immunology Center. Dr. Perez spends sixty percent of his time in his laboratory researching ocular immunology and transplantation. He complements this with his work as Director of the Ocular Surface Program, evaluating and treating patients with ocular inflammatory diseases and conditions of the anterior segment. In addition to ocular surface, he will also manage patients with uveitis, transplantation and diseases of the eye that also have inflammation. Dr. Perez’s laboratory focuses primarily on researching immunology of corneal transplantation and ocular Graft vs Host Disease (GVHD).  Dr. Perez and his colleagues use a mouse model of corneal transplantation and Ocular GVHD that allows for translational research relevant to patients with penetrating keratoplasty and ocular GVHD. Dr. Perez’s grant from the National Eye Institute supports his lab’s work on the immunological mechanisms involved in high-risk corneal transplant rejection and ocular GVHD.   Members of Dr. Perez’s lab have also used the mouse eye as an in vivo imaging platform to study T cell recruitment and in situ activation. The aim of this work is to develop a translational research clinic to study the natural history of disease progression in ocular GVHD and to test the role of cytokines in this process.  One of the most innovative aspects of this program is the multidisciplinary team—consisting of scientists from the ophthalmology, basic immunology, and oncology units—whose members work together to comprehensively tackle the research and care of patients with GVHD. The knowledge and development of potential new preventive therapies that is being generated in the laboratory will have a direct translational impact on the care of Duke Eye Center patients with GVHD.
Dr. John Sheppard M.D., is the President of Virginia Eye Consultants, and he oversees our overall mission of providing a leading academic, clinical, and research center for excellence in ophthalmology. Dr. Sheppard is a board-certified and fellowship-trained corneal eye surgeon, and he specializes in such areas as corneal transplantation, dry eye syndrome, uveitis, cataract surgery, glaucoma, and premium lens implants. His commitment to performing the highest quality of eye care solutions has led to Dr. Sheppard receiving the American Academy of Ophthalmology Honor Award, and he has also been named one of The Best Doctors in America since 2002. Dr. Sheppard is originally from Pittsburgh. He received a full Armed Forces Health Professions Scholarship, under which he completed his bachelor’s, master’s and medical degrees from Brown University in Rhode Island. For four years, he served with the U.S. Navy, acting as the 6th Fleet Medical Officer and Chief of Family Practice.  Following his time in the military, Dr. Sheppard completed a residency in ophthalmology at the University of Pittsburgh Eye and Ear Institute. He then entered a fellowship at the University of California Francis I. Proctor Research Foundation in San Francisco. During this time, he was given the esteemed Heed-Knapp, Burroughs-Wellcome and NIH National Research Fellowship grants for his work in corneal disease, uveitis, third world blindness, and ocular immunology. In 1989, Dr. Sheppard joined the Eastern Virginia Medical School (EVMS) faculty and is now Professor of Ophthalmology, Microbiology, and Molecular Biology. He also serves as Research Director of the Ophthalmology Residency Program at EVMS. As Clinical Director of the Thomas R. Lee Center for Ocular Pharmacology, he not only coordinates clinical trials, but is also instrumental in translational research bringing preclinical studies into practice. He holds a patent for photodynamic therapy of the ocular surface. During a period of major sociopolitical changes in transplantation reimbursement, he was Chairman of the Board of the Lions Bank of Eastern Virginia and now serves as a Medical Director. Dr. Sheppard is actively involved in numerous clinical trials and has participated as principal investigator in over 110 clinical research trials sponsored by many major pharmaceutical companies and for the U.S. Food and Drug Administration. In addition, Dr. Sheppard has served on the medical advisory board for over 41 pharmaceutical and medical device companies. He has authored over 110 peer review abstracts, journal articles, and chapters.
Dr. Joseph Tauber, M.D., is a member of Aldeyra’s Anterior Segment Scientific Advisory Board.  Dr. Tauber specializes in anterior segment surgery, corneal transplantation, the treatment of corneal and external diseases and laser vision correction procedures. A board-certified ophthalmologist, Dr. Tauber received his doctorate from Harvard Medical School, his training in internal medicine at Beth Israel Hospital and in ophthalmology at Tufts-New England Medical Center, all located in Boston, Massachusetts. Dr. Tauber enhanced his medical education with two years of ocular immunology and corneal and external disease fellowship training at the Massachusetts Eye and Ear Infirmary. Dr. Tauber is an internationally recognized authority in the field of ocular surface diseases, including dry eye and meibomitis management. He has been a Principal Investigator in dozens of clinical research programs, including those that led to the approval of the only two medications approved by the FDA for the treatment of dry eye – Restasis and Xiidra. Dr. Tauber continues to advance treatment options with active involvement in Scientific Advisory Boards for a number of pharmaceutical firms. Dr. Tauber’s Ocular Surface Disease Center provides patients an opportunity to benefit from his experience in dry eye and ocular surface healing problems together with the most modern diagnostic and treatment options available anywhere. Dr. Tauber has been performing laser vision correction surgery since 1989, as one of the first ophthalmologists in the U.S. doing these surgeries. He has trained ophthalmologists across the U.S. in these procedures, and has experience with all the major lasers in use today. Avidly involved in research for almost three decades, Dr. Tauber has been a principal investigator in over 125 research studies of high-risk corneal transplantation, inflammation and allergic eye diseases, corneal infectious diseases and numerous studies related to dry eye syndrome. He is a member of the American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, Kansas City Society of Ophthalmology and Otolaryngology, the American Society of Cataract and Refractive Surgery and the Cornea Society. Dr. Tauber has written five book chapters and over 60 articles for such prestigious medical journals as Ophthalmology, Investigative Ophthalmology and Visual Science, Journal of Cataract and Refractive Surgery and Cornea. He has been awarded the Heed Ophthalmic Foundation Fellowship Award and the National Eye Institute Individual NRSA Award.